Skip to main content
. 2022 Sep 13;3:932530. doi: 10.3389/fpain.2022.932530

Figure 7.

Figure 7

Myelin oligodendrocyte glycoprotein (MOG) induces lumbar spinal cord dorsal horn Iba1 immunoreactivity that is reversed by daily systemic administration of the TLR2–TLR4 antagonist (+)-Naltrexone [(+)-NTX]. Sprague-Dawley (SD) from Experiment 2 received intradermal low-dose (0, 8, and 16 μg) myelin oligodendrocyte glycoprotein (MOG). Spinal cord tissue was collected on day 30 post-MOG administration and during 13 days of daily (+)-NTX administration. Both doses of MOG increased expression of the microglial immunoreactivity marker Iba1 in dorsal horn of lumbar spinal cord, which was reversed to 0 μg MOG control levels by (+)-NTX administration. Main effects of MOG [F(2, 86) = 9.66; p < 0.001], (+)-NTX [F(2, 86) = 19.57; p < 0.0001], and interaction between MOG and (+)-NTX [F(2, 86) = 7.81; p < 0.001]. N = 3–8/group, with 2–4 pictures analyzed per subject. Post-hocs: * indicates significant differences between groups (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).